Skip to main content
SpringerLink
Log in

Risk of hepatotoxicity with tocilizumab under review

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. see Reactions 1755 p2; 803396852

References

  1. Therapeutic Goods Administration. Tocilizumab and hepatotoxicity. Internet Document : 11 Jul 2019. Available from: URL: https://www.tga.gov.au/publication-issue/tocilizumab-and-hepatotoxicity.

  2. Medicines and Healthcare products Regulatory Agency (UK). Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation. Drug Safety Update 12: 4-6, No. 12, Jul 2019. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/818083/July-2019-PDF.pdf.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of hepatotoxicity with tocilizumab under review. Reactions Weekly 1763, 6 (2019). https://doi.org/10.1007/s40278-019-65098-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-65098-5

Search

Navigation